Profile data is unavailable for this security.
About the company
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
- Revenue in CAD (TTM)0.00
- Net income in CAD-15.74m
- Incorporated2025
- Employees8.00
- LocationSernova Biotherapeutics Inc700 Collip Circle, Ste 114LONDON N6G 4X8CanadaCAN
- Phone+1 (519) 858-5184
- Fax+1 (519) 858-5099
- Websitehttps://sernova.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cheelcare Inc | 809.92k | -2.24m | 33.77m | -- | -- | 43.81 | -- | 41.69 | -0.2197 | -0.2197 | 0.0964 | 0.0393 | 0.679 | -- | 3.61 | -- | -188.00 | -- | -335.28 | -- | 54.44 | -- | -276.88 | -- | 1.29 | -3.98 | 0.3945 | -- | -- | -- | -50.62 | -- | -- | -- |
| Perimeter Medical Imaging AI Inc | 2.55m | -19.44m | 36.05m | 56.00 | -- | 6.49 | -- | 14.11 | -0.2041 | -0.2041 | 0.0267 | 0.0424 | 0.1742 | 13.93 | 11.78 | 44,044.51 | -132.55 | -69.07 | -168.92 | -88.85 | 59.01 | -- | -760.93 | -4,063.70 | 1.17 | -- | 0.0284 | -- | 109.70 | -- | 4.57 | -- | -- | -- |
| Conavi Medical Corp | 9.12m | -20.52m | 42.40m | 4.00 | -- | -- | -- | 4.65 | -0.386 | -0.386 | 0.1586 | -0.2349 | 1.08 | -- | -- | -- | -243.23 | -- | -613.64 | -- | 83.61 | -- | -224.91 | -- | 0.9655 | -1.23 | 10.61 | -- | -- | -- | -- | -- | -- | -- |
| Covalon Technologies Ltd | 32.82m | 2.06m | 43.08m | -- | 21.19 | 1.39 | 14.30 | 1.31 | 0.0736 | 0.0736 | 1.18 | 1.12 | 0.9662 | 2.03 | 6.92 | -- | 6.06 | -5.25 | 6.84 | -6.53 | 53.24 | 52.97 | 6.27 | -6.68 | 6.40 | -- | 0.0683 | -- | 5.29 | 19.43 | -22.91 | -- | 32.67 | -- |
| Sernova Biotherapeutics Inc | 0.00 | -15.74m | 48.82m | 8.00 | -- | -- | -- | -- | -0.048 | -0.048 | 0.00 | -0.0753 | 0.00 | -- | -- | 0.00 | -379.75 | -102.72 | -- | -177.86 | -- | -- | -- | -- | -- | -19.61 | -- | -- | -- | -- | 51.10 | -- | -- | -- |
| Medmira Inc | 233.00k | -4.04m | 53.08m | 65.00 | -- | -- | -- | 227.82 | -0.0058 | -0.0058 | 0.0003 | -0.0333 | 0.0543 | 0.3625 | 0.1737 | -- | -94.02 | -62.12 | -- | -- | 69.69 | 65.17 | -1,732.61 | -311.65 | 0.0565 | -2.96 | -- | -- | -41.70 | -23.52 | -36.02 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| CATAM Asset Management AGas of 31 Dec 2025 | 150.00k | 0.05% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 0.00 | 0.00% |
